31

Rudin D. Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study. Gastrointest Endosc 2008; 67:190. [More details]

30

Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007; 132(5):2022-44. [More details]

29

Abdel Aziz AM, Lehman GA. Pancreatitis after endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2007; 13(19):2655-68. [More details]

28

Lieb JG 2nd, Draganov PV. Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2007; 13(26):3567-74. [More details]

27

Rudin D, Kiss A, Wetz RV, Sottile VM. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007; 22(7):977-83. [More details]

26

Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102(8):1781-8. [More details]

25

Andriulli A, Forlano R, Napolitano G, Conoscitore P, Caruso N, Pilotto A, et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75(2-3):156-63. [More details]

24

Nikolopoulou VN. High dose of octreotide as a prophylaxis of post-ERCP pancreatitis - Response. Gastrointest Endosc 2007; 66(2):421. [More details]

23

Kaya E. Octreotide and post-ERCP pancreatitis. Gastrointest Endosc 2007; 66(2):420-1. [More details]

22

Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007; 66(6):1126-32. [More details]

21

Kitagawa M, Hayakawa T. Antiproteases in the Treatment of Acute Pancreatitis. JOP. J Pancreas (Online) 2007; 8(4 Suppl):518-525. [More details]

20

Kisli E, Baser M, Aydin M, Guler O. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis. Hepatogastroenterology 2007; 54(73):250-3. [More details]

19

Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65(4):624-32. [More details]

18

Frank CD, Adler DG. Post-ERCP pancreatitis and its prevention. Nat Clin Pract Gastroenterol Hepatol 2006; 3(12):680-8. [More details]

17

Vila JJ, Jimenez FJ, Prieto C, Borobio E, Juanmartinena JF, Borda F. Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, non-randomized study. Gastroenterol Hepatol 2006; 29(4):231-6. [More details]

16

Bali MA, Golstein P, Deviere J, Chatterjee N, Matos C. Evaluation of somatostatin inhibitory effect on pancreatic exocrine function using secretin-enhanced dynamic magnetic resonance cholangiopancreatography: a crossover, randomized, double blind, placebo-controlled study. Pancreas 2006; 32(4):346-50. [More details]

15

Gui Q, Xiong G, Zhi L, Wu S. Efficacy of gabexate mesilate on prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Chinese Journal of Gastroenterology 2006; 11(11):663-5. [More details]

14

Whitcomb DC. Acute pancreatitis. Reply. N Engl J Med 2006; 355(9):961; author reply 961. [More details]

13

Testoni PA. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story. Gastrointest Endosc 2006; 64(5):732-4. [More details]

12

Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006; 64(5):726-31. [More details]

11

Xiong GS, Wu SM, Zhang XW, Ge ZZ. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 2006; 39(1):85-90. [More details]

10

Pungpapong S, Kongkam P, Rerknimitr R, Kullavanijaya P. Experience on endoscopic retrograde cholangiopancreatography at tertiary referral center in Thailand: risks and complications. J Med Assoc Thai 2005; 88(2):238-46. [More details]

9

Singh VP, Chari ST. Protease inhibitors in acute pancreatitis: Lessons from the bench and failed clinical trials. Gastroenterology 2005; 128(7):2172-4. [More details]

8

Gottumukkala SR. Prevention of post-ERCP pancreatitis: are there any pearls for sale?. Gastroenterology 2004; 127(1):348-50. [More details]

7

Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2(8):713-8. [More details]

6

Orbuch M. Optimizing outcomes in acute pancreatitis. Clin Fam Pract 2003; 6(3):607-29. [More details]

5

Cotton PB. ERCP: Risks, Prevention, and Management. In: Advanced Digestive Endoscopy Series: ERCP Section Cotton PB, Ed Charleston, SC, USA: The Digestive Disease Center at the Medical University of South Carolina (MUSC). E-book. [More details]

4

Boix E, López P, Pérez-Mateo M, Picó A. Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment. J Endocrinol Invest 2004; 27(6):613-4. [More details]

3

Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59(7):845-64. [More details]

2

Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy 2004; 36(1):8-16. [More details]

1

Freeman ML. Prevention of post-ERCP pancreatitis: Pharmacologic solution or patient selection and pancreatic stents?. Gastroenterology 2003; 124(7):1977-80. [More details]